.
concentration ([Ca 2ϩ ]i) in pulmonary arterial smooth muscle cells (PASMC); however, these antagonists can also decrease [Ca 2ϩ ]i. To determine whether MLCK and ROK antagonists alter Ca 2ϩ signaling in HPV, we measured the effects of ML-9, ML-7, Y-27632, and HA-1077 on [Ca 2ϩ ]i, Ca 2ϩ entry, and Ca 2ϩ release in rat distal PASMC exposed to hypoxia or depolarizing concentrations of KCl. We performed parallel experiments in isolated rat lungs to confirm the inhibitory effects of these agents on pulmonary vasoconstriction. Our results demonstrate that MLCK and ROK antagonists caused concentration-dependent inhibition of hypoxia-induced increases in [Ca 2ϩ ]i in PASMC and HPV in isolated lungs and suggest that this inhibition was due to blockade of Ca 2ϩ release from the sarcoplasmic reticulum and Ca 2ϩ entry through store-and voltage-operated Ca 2ϩ channels in PASMC. Thus MLCK and ROK antagonists might block HPV by inhibiting Ca 2ϩ signaling, as well as the actin-myosin interaction, in PASMC. If effects on Ca 2ϩ signaling were due to decreased phosphorylated myosin light chain concentration, their diversity suggests that MLCK and ROK antagonists may have acted by inhibiting myosin motors and/or altering the cytoskeleton in a manner that prevented achievement of required spatial relationships among the cellular components of the response. release from the sarcoplasmic reticulum (SR) and Ca 2ϩ entry through voltage-operated Ca 2ϩ channels (VOCC) (57, 71) . Recently, we and others demonstrated that Ca 2ϩ influx through store-operated Ca 2ϩ channels (SOCC) is required for HPV (42, 66, 77) . SOCC are activated by depletion of SR Ca 2ϩ stores (44, 45) . The resulting Ca 2ϩ influx, known as capacitative Ca 2ϩ entry (CCE), is an important determinant of [Ca 2ϩ ] i in a wide variety of vasomotor responses (19, 35, 50, 54) .
Numerous studies in smooth muscle indicate that, at high concentrations, Ca 2ϩ forms complexes with calmodulin, which activate myosin light chain (MLC) kinase (MLCK), causing phosphorylation of MLC (29) . Phosphorylated MLC (P-MLC) then facilitates stimulation of myosin ATPase activity by actin, leading to cross-bridge cycling and contraction. Evidence indicates that this sequence of events occurs during HPV. Hypoxia increased MLC phosphorylation in PASMC and pulmonary arteries in association with contraction (33, 38, 68, 69, 83) . In pulmonary arteries, tension development during hypoxia correlated directly with P-MLC concentration ([P-MLC]) and was abolished by the MLCK antagonist ML-9 (83) .
[P-MLC] can be increased not only by activation of MLCK, but also by inhibition of myosin phosphatase (MP), the enzyme that dephosphorylates P-MLC (28, 29) . In vascular smooth muscle, the principal regulator of MP appears to be Rho kinase (ROK). ROK is activated by the GTP-complexed form of the monomeric GTPase, Rho, which is produced when G proteinlinked receptors interact with their ligands (52, 56) . ROK inhibits MP by phosphorylating its myosin-binding subunit and/or by activating an endogenous inhibitor known as CPI-17 (17) . ROK may also phosphorylate MLC directly (31) . By these means, ROK can increase [P-MLC] at a given rate of MLC phosphorylation via MLCK. Because MLCK is activated by Ca 2ϩ -calmodulin complexes produced in proportion to [Ca 2ϩ ] i , activation of ROK is said to increase myofilament Ca 2ϩ sensitivity, defined as an increase in contractile force at a given [Ca 2ϩ ] i (17, 53) . In rat distal pulmonary arteries, the slowly developing phase 2 of hypoxic contraction was associated with an elevated, but constant, [Ca 2ϩ ] i (46) . Hypoxia increased ROK activity in PASMC, and this increase was blocked by exoenzyme C3 or toxin B, antagonists of Rho (68) . Hypoxia increased phosphorylation of MLC and the myosin-binding subunit of MP and decreased MP activity in PASMC (69) . Y-27632 and HA-1077, antagonists of ROK, blocked hypoxia-induced MP inactivation and MLC phosphorylation in PASMC, phase 2 hypoxic contraction in distal pulmonary arteries, and HPV in isolated lungs and intact animals (16, 39, 47, 68, 69 ] i responses to norepinephrine in rat mesenteric artery and rat aorta (18) . Similarly, HA-1077 blocked increases in [Ca 2ϩ ] i induced by norepinephrine in rat aorta (18, 59) and by bradykinin or thapsigargin in porcine aortic endothelial cells (72) . ML-9 or a related MLCK antagonist, ML-7, blocked [Ca 2ϩ ] i responses to KCl in coronary artery (80) ; methacholine, thapsigargin, or KCl in guinea pig trachealis (23) ; bradykinin, thapsigargin, or shear stress in endothelial cells (43, 58, 72, 73) ; and UTP in bovine adrenocortical fasciculata cells (30) . In endothelial and adrenocortical fasciculata cells, isolated trachealis, and human blood monocytes, ML-9 blocked CCE through SOCC (23, 30, 43, 61) . In portal vein myocytes, ML-7 and ML-9 blocked norepinephrine-induced increases in currents through nonspecific cation channels (2) . These results suggest that, in addition to inhibition of the actin-myosin interaction, antagonists of MLCK and ROK can reduce [Ca 2ϩ ] i through effects on Ca 2ϩ channel activation.
It is not known whether MLCK and ROK antagonists alter Ca 2ϩ signaling during HPV, which requires Ca 2ϩ release from the SR and Ca 2ϩ entry through VOCC and SOCC; therefore, we measured the effects of ML-9, ML-7, Y-27632, and HA-1077 on [Ca 2ϩ ] i , Ca 2ϩ entry, and Ca 2ϩ release in rat distal PASMC exposed to hypoxia or depolarizing concentrations of KCl. Parallel experiments were performed in isolated rat lungs to determine the effects of these agents on pulmonary vasoconstriction.
METHODS

PASMC
As previously described (65, 66) , distal (Ͼ4th generation) intrapulmonary arteries were dissected from lungs of pentobarbital sodium (65 mg/kg ip)-anesthetized male Wistar rats (300 -500 g body wt). The luminal surfaces were rubbed with a cotton swab for removal of endothelial cells from the vascular segments. Smooth muscle cells were obtained by enzymatic digestion and cultured for 3-6 days on glass coverslips in Smooth Muscle Growth Medium 2 (Clonetics, Walkersville, MD) containing 5% serum in a humidified atmosphere of 5% CO 2-95% air at 37°C. Serum concentration in the medium was decreased to 0.3% 24 h before an experiment to stop cell growth. Cellular purity was Ͼ95%, as assessed by morphological appearance under phase-contrast microscopy and immunofluorescence staining for ␣-actin (65, 66) .
For measurement of [Ca 2ϩ ]i and Ca 2ϩ entry, cells were incubated with 7.5 M fura 2-AM (Molecular Probes, Eugene, OR) for 60 min at 37°C under an atmosphere of 5% CO 2-95% air. Coverslips were then mounted in a closed polycarbonate chamber clamped to a heated aluminum platform (model PH-2, Warner Instrument, Hamden, CT) on the stage of a inverted microscope (TSE 100 Ellipse, Nikon, Melville, NY) and perfused at 0.5 ml/min with Krebs-Ringer bicarbonate solution (KRBS), which contained (in mM) 118 NaCl, 4.7 KCl, 2.5 CaCl 2, 0.57 MgSO4, 1.18 KH2PO4, 25 NaHCO3, and 10 glucose. Perfusate was equilibrated in heated reservoirs with 5% CO2 and either 16% O2 (normoxia) or 4% O2 (hypoxia) and led to the chamber through stainless steel tubing. For depolarization of the cells, perfusate KCl was increased to 60 mM and NaCl was decreased to 62.7 mM. Chamber temperature was maintained at 37°C with an in-line heat exchanger and dual-channel heater controller (models SF-28 and TC-344B, Warner Instrument).
After removal of extracellular dye by 10 min of normoxic perfusion, [Ca 2ϩ ]i was determined at 6-to 60-s intervals from the ratio of fura 2 fluorescence emitted at 510 nm after excitation at 340 nm to that after excitation at 380 nm (F 340/F380) measured in 10 -30 cells using a xenon arc lamp, interference filters, an electronic shutter, a ϫ20 fluorescence objective, and a cooled charge-coupled device imaging camera. Data were collected online with InCyte software (Intracellular Imaging, Cincinnati, OH). [Ca 2ϩ ]i was estimated from F340/F380 measured in vitro in calibration solutions with 0 -1,350 nM Ca 2ϩ (Molecular Probes). After a 5-min control period, cells were exposed to 4% O2 for 20 min or 60 mM KCl for 15 min followed by a 10-min normoxic recovery period, during which perfusate KCl concentration ([KCl]) was normal. During exposure to hypoxia or
, antagonists of MLCK (ML-9 and ML-7) or ROK (Y-27632 and HA-1077) were added to the perfusate in amounts sufficient to achieve the desired concentrations: 10, 30, or 100 M ML-9 (n ϭ 4/group), 1, 10, or 100 M ML-7 (n ϭ 4 -5/group), 1, 3, or 10 M Y-27632 (n ϭ 4 -5/group), and 10, 30, or 100 M HA-1077 (n ϭ 4 -5/group). In each experiment, cells were exposed to hypoxia or high [K ϩ ] and treated with a single concentration of a single antagonist. Untreated cells from the same isolate served as controls (n ϭ 4 -9).
To assess CCE, we perfused PASMC with normoxic (16% O 2) or hypoxic (4% O 2) Ca 2ϩ -free KRBS containing 0.5 mM EGTA to chelate residual Ca 2ϩ , 5 M nifedipine to prevent Ca 2ϩ entry through L-type VOCC, and 10 M cyclopiazonic acid (CPA) to deplete SR Ca 2ϩ stores. In our first series of experiments, we estimated CCE after 10 min by measuring the increase in [Ca 2ϩ ]i caused by restoration of perfusate [Ca 2ϩ ] to 2.5 mM in cells exposed to 10, 30, or 100 M ML-9 (n ϭ 4 -5/group), 1, 3, or 10 M Y-27632 (n ϭ 4 -5/group), or 10, 30, or 100 M HA-1077 (n ϭ 3-4/group). Antagonists were given simultaneously with CPA. Untreated cells from the same isolate served as controls (n ϭ 4 -10). In our second series of experiments, we estimated CCE after 10 min by measuring the rate at which 200 M MnCl 2 quenched fura 2 fluorescence excited at 360 nm over the ensuing 10 min in untreated cells (n ϭ 3 during normoxia and n ϭ 4 during hypoxia) and cells exposed to hypoxia ϩ ML-9 (100 M, n ϭ 4) or hypoxia ϩ Y-27632 (10 M, n ϭ 4).
To assess Ca 2ϩ release from SR, we perfused PASMC with normoxic Ca 2ϩ -free KRBS containing 0.5 mM EGTA to chelate residual Ca 2ϩ . After 10 min, the cells were perfused with hypoxic (4% O2) Ca 2ϩ -free KRBS for 5 min. We estimated Ca 2ϩ release as the maximum increase in [Ca 2ϩ ]i caused by hypoxia in PASMC exposed to 100 M ML-9 (n ϭ 4) or 10 M Y-27632 (n ϭ 4), which were added to the perfusate 8 min before hypoxia. Untreated cells served as controls (n ϭ 4).
To assess voltage-operated Ca 2ϩ entry, we perfused PASMC with normoxic Ca 2ϩ -free KRBS containing 0.5 mM EGTA to chelate residual Ca 2ϩ , 50 M SKF-96365 to prevent CCE (65), and 60 mM KCl to cause depolarization. After 10 min, we estimated voltageoperated Ca 2ϩ entry from the rate at which 200 M MnCl2 quenched fura 2 fluorescence in PASMC exposed to 100 M ML-9 (n ϭ 3) or 5 M nifedipine (n ϭ 2). Untreated cells served as controls (n ϭ 3).
Isolated Lungs
Male Wistar rats (200 -400 g body wt) were given heparin (1,000 U ip) and anesthetized 20 -30 min later with pentobarbital sodium (65 mg/kg ip). A tracheostomy was performed, and the animal was ventilated with room air at a tidal volume of 10 ml/kg and rate of 30 min Ϫ1 (rodent ventilator 883, Harvard Apparatus, Holliston, MA). After exsanguination from the femoral artery, the ventilating gas was changed to 16% O2-5% CO2. A thoracotomy was performed, and cannulas were inserted into the main pulmonary artery and left atrium, which drained into a heated reservoir. The lungs were perfused with a peristaltic pump (Ismatec Reglo Analog Pump, Cole Parmer, Vernon Hills, IL) at 40 ml ⅐ kg Ϫ1 ⅐ min Ϫ1 with KRBS containing (in mM) 118 NaCl, 4.7 KCl, 0.57 MgSO4, 1.18 KH2PO4, 25 NaHCO3, and 10 glucose. Ficoll (4 g/dl) and sodium meclofenamate (3.1 M) were added to provide oncotic pressure and prevent release of vasodilator prostaglandins. After the vasculature was flushed free of residual blood, the perfusate was recirculated. In KCl experiments, lungs were perfused with a 70:30 mixture of KRBS and the animal's own blood to mitigate edema formation caused by high perfusion pressures. Temperature in the left atrial effluent was maintained at 37°C with a heat exchanger. Pulmonary arterial pressure (Ppa), left atrial pressure, and tracheal pressure were measured relative to the bottom of the lung with pressure transducers (model P10EZ, Spectramed, Oxnard, CA) and recorded with a computer-linked recording system (Powerlab, ADInstruments, Colorado Springs, CO). End-expiratory tracheal and left atrial pressures were maintained at 3-4 and Ͻ0mmHg, respectively. Since perfusate flow was also constant, increases in Ppa were assumed to reflect pulmonary vasoconstriction.
After a 20-min stabilization period, lungs were subjected to one of two protocols: 1) four alternating exposures to ANG II (0.05-g bolus into the main pulmonary artery) and hypoxia (ventilation with 2% O 2 for 5 min) at 5-to 10-min intervals or 2) progressive 5-10 mM increases in perfusate [KCl] at 5-to 10-min intervals until Ppa achieved a maximum or the lungs developed edema. In protocol 1, antagonists of MLCK (30 or 100 M ML-9 or ML-7) or ROK (3, 10, 30, or 100 M Y-27632 or HA-1077) were added to the perfusate after the second hypoxic exposure (n ϭ 4 -6 at each antagonist concentration). In protocol 2, the antagonists (10, 30 or 100 M ML-9, ML-7, Y-27632, or HA-1077; n ϭ 4 -5 at each antagonist concentration) were given 10 -15 min before administration of KCl. In both protocols, a lung was exposed to a single concentration of a single antagonist. Untreated lungs served as controls (n ϭ 9 -10).
Drugs and Materials
Stock solutions of Y-27632, HA-1077, SKF-96935, and KCl were made up in water and stored at 4°C. Stock solutions of ML-9, ML-7, and ANG II were made up in water on the day of the experiment. Stock solutions of nifedipine and CPA were made up in DMSO and stored at Ϫ20°C. ML-9, ML-7, Y-27632, and nifedipine were obtained from CalBiochem (La Jolla, CA). All other agents were obtained from Sigma Chemical (St. Louis, MO).
Data Analysis
To estimate the concentrations at which MLCK or ROK antagonists inhibited responses by 50% (IC 50), the mean ⌬[Ca 2ϩ ]i or maximum ⌬Ppa elicited by hypoxia or KCl in antagonist-treated preparations was expressed as a percentage of the corresponding mean values in untreated preparations. To obtain IC 50, we used an iterative least-squares method to fit the relationship between percent response and antagonist concentration to the Hill equation (66, 77) . On two occasions in PASMC, mean ⌬[Ca 2ϩ ]i at the high antagonist concentration was either negative (Fig. 1, A and B: ML-7) or plateaued at Ͼ0 nM (Fig. 2, A and B: Y-27632, hypoxia). In these cases, average ⌬[Ca 2ϩ ]i at that concentration was subtracted from all observations before data were expressed as percentage of control.
In PASMC isolates from a specific animal, we measured [Ca 2ϩ ]i in each cell and then entered the average of these values into statistical analysis as an n of 1. Thus, in PASMC and isolated lung experiments, n refers to the number of animals. Statistical analyses were performed using Student's t-test or ANOVA. If a significant interaction F-ratio was obtained with the latter, pair-wise comparison of individual means was performed by calculating the least significant difference. Comparisons of group means with control were performed using Dunnett's test. Differences were considered significant when P Ͻ 0.05. Values are means Ϯ SD unless otherwise stated.
RESULTS
Responses to Hypoxia
PASMC. Hypoxia caused rapid increases in PASMC [Ca 2ϩ ] i that were sustained for the duration of exposure (Fig. 1A) . ML-9 and ML-7, antagonists of MLCK, caused concentrationdependent inhibition of this response (Fig. 1, A and B) , with estimated IC 50 of 6.3 and 10.8 M, respectively (Fig. 1C) . Y-27632 and HA-1077, antagonists of ROK, also inhibited [Ca 2ϩ ] i responses to hypoxia in a concentration-dependent manner (Fig. 1, A Fig. 2A) . The maximum increase in [Ca 2ϩ ] i induced by CPA in the absence of extracellular Ca 2ϩ averaged 126 Ϯ 66 nM in normoxic control PASMC and was not altered by hypoxia or antagonists of MLCK and ROK. In contrast (Fig.  2) , the maximum increase in [Ca 2ϩ ] i caused by subsequent restoration of extracellular Ca 2ϩ was markedly enhanced by hypoxia, as we observed previously (66) . Moreover, this enhancement was abolished by ML-9, Y-27632, or HA-1077 (IC 50 ϭ 6.4, 1.2, and 23.9 M, respectively; Fig. 2C ). These IC 50 values were virtually identical to those estimated for [Ca 2ϩ ] i responses to hypoxia (6.3, 2.5, and 20.2 M, respectively; Fig. 1C ). To confirm that these effects were due to inhibition of Ca 2ϩ influx through SOCC, rather than enhance- ment of Ca 2ϩ efflux or uptake, we measured the effects of ML-9 and Y-27632 on quenching of fura 2 fluorescence by Mn 2ϩ in PASMC perfused with Ca 2ϩ -free KRBS containing CPA and nifedipine (Fig. 3) . Hypoxia increased the rate at which Mn 2ϩ quenched fura 2 fluorescence more than twofold. This increase was eliminated by ML-9 (100 M) or Y-27632 (10 M).
The MLCK antagonist ML-9 also inhibited CCE during normoxia (Fig. 2) . The IC 50 for this effect (5 M) was equivalent to that observed for ML-9 vs. hypoxia-induced increases in CCE (6.4 M; Fig. 2C ) or [Ca 2ϩ ] i (6.3 M; Fig. 1C ). In contrast, neither ROK antagonist (Y-27632 nor HA-1077) altered CCE during normoxia (Fig. 2) .
In untreated control PASMC perfused with Ca 2ϩ -free KRBS, hypoxia caused a transient increase in [Ca 2ϩ ] i (128 Ϯ 19 nM), indicating intracellular Ca 2ϩ release (Fig. 4) . This increase was virtually abolished in cells treated with 100 M ML-9 or 10 M Y-27632 (17 Ϯ 14 and 18 Ϯ 11 nM, respectively, P Ͻ 0.0001). Baseline [Ca 2ϩ ] i under normoxic Ca 2ϩ -free conditions averaged 106 Ϯ 52 nM, did not differ among groups, and was not altered by ML-9 or Y-27632.
Isolated lungs. Figure 5 shows representative recordings of four alternating exposures to ANG II and hypoxia in untreated control lungs and lungs treated with an antagonist of MLCK (ML-9) or ROK (HA-1077) after the second exposure. Before treatment, ANG II and hypoxia caused rapid reversible increases in Ppa at constant flow, left atrial pressure, and endexpiratory tracheal pressure, indicating vasoconstriction. Peak ⌬Ppa from baseline caused by hypoxia at the second exposure averaged 10.6 Ϯ 1.3 mmHg in control lungs and did not differ among groups. Peak ⌬Ppa at subsequent exposures, expressed as a percentage of its value at the second exposure, is shown in Fig. 6A . In control lungs, hypoxic pressor responses decreased slightly during the third and fourth exposures but remained Ͼ80% of the response at the second exposure. Antagonists of MLCK (ML-9 and ML-7) and ROK (Y-27632 and HA-1077) caused marked inhibition of pressor responses to hypoxia. Estimated IC 50 values for ML-9, ML-7, Y-27632, and HA-1077 vs. hypoxic pressor responses were 29.0, 27.7, 31.2, and 54.9 M, respectively (Fig. 6B) . These values were 0.4 -1 log unit greater than IC 50 values vs. [Ca 2ϩ ] i responses to hypoxia in PASMC (6.3, 10.8, 2.5, and 20.2 M, respectively; Fig. 1C ). Effects on pressor responses to ANG II were similar (data not shown). 
Responses to Depolarization
PASMC. On exposure to 60 mM KCl, [Ca 2ϩ ] i exhibited an initial rapid overshoot followed by a sustained elevation (Fig. 7A) . The peak increase caused by depolarization was usually larger than that caused by hypoxia (Fig. 1) . ML-9 and ML-7, antagonists of MLCK, caused concentration-dependent inhibition of this response (IC 50 ϭ 19.1 and 4.6 M, respectively; Fig. 7 ). Similar to their lack of effect on CCE during normoxia (Fig. 2) , the ROK antagonists Y-27632 (10 M) and HA-1077 (100 M) did not alter depolarization-induced increases in [Ca 2ϩ ] i during normoxia (Fig. 7) . To confirm that the inhibitory effect of ML-9 on the [Ca 2ϩ ] i response to depolarization was due to inhibition of Ca 2ϩ entry through VOCC, we measured Mn 2ϩ quenching of fura 2 fluorescence in PASMC perfused with Ca 2ϩ -free KRBS containing 60 mM KCl to activate VOCC and 50 M SKF-96365 to block CCE through SOCC (65, 66) . Under these conditions, 100 M ML-9 and 5 M nifedipine markedly reduced the rate at which Mn 2ϩ quenched fura 2 fluorescence (Fig. 8) . Isolated lungs. Figure 9 shows representative recordings of pressor responses to increased perfusate [KCl] in untreated control lungs and lungs treated with an antagonist of MLCK (ML-9) or ROK (HA-1077). In control lungs, increases in perfusate [KCl] caused progressive increases in Ppa from 9.7 Ϯ 0.62 mmHg at 5 mM to 33.8 Ϯ 2.8 mmHg at 40 mM, the highest concentration achieved in all lungs of this group. Antagonists of MLCK and ROK inhibited pressor responses to KCl (Fig. 10A) . Estimated IC 50 values for ML-9, ML-7, Y-27632, and HA-1077 were 57.3, 79.0, 6.0, and 11.6 M, respectively (Fig. 10B) . In the case of ML-9 and ML-7, these IC 50 values were 0.5-1.2 log units greater than IC 50 values measured vs. [Ca 2ϩ ] i responses to depolarization in PASMC (19.1 and 4.6 M, respectively; Fig. 7B ). This was not true for the ROK antagonists Y-27632 and HA-1077, which inhibited pressor responses to depolarization in isolated lungs (Fig. 10B ) but had no effect on [Ca 2ϩ ] i responses to depolarization in PASMC (Fig. 7B ).
DISCUSSION
In our prior studies (66, 77) , we found that HPV in isolated lungs required Ca 2ϩ entry through SOCC and VOCC. In the present study, we confirm that HPV was blocked by antagonists of MLCK or ROK and test the possibility that this inhibition was caused by effects on Ca 2ϩ signaling in PASMC. In rat distal PASMC, hypoxia induced a rapid reversible increase in [Ca 2ϩ ] i (Fig. 1 ) and enhanced CCE (Figs. 2 and 3) , as previously observed in this preparation (66 (Fig. 4) responses to hypoxia (Fig. 1) by blocking hypoxia-induced release of Ca 2ϩ from the SR, thereby preventing SOCC activation. Neither ML-9 nor Y-27632 alone altered [Ca 2ϩ ] i in PASMC exposed to Ca 2ϩ -free conditions; therefore, it is unlikely that these antagonists inhibited hypoxia-induced Ca 2ϩ release by causing prior depletion of SR Ca 2ϩ stores (43) . Rather, they must have interfered with the poorly understood mechanisms by which hypoxia activates Ca 2ϩ release in PASMC.
With respect to the second possibility, we found that hypoxia did not alter Ca 2ϩ release induced by CPA but, nevertheless, enhanced CPA-induced CCE (see RESULTS, Figs. 2 and 3) (66), suggesting that hypoxia facilitated transduction pathways linking store depletion to SOCC activation. Antagonists of MLCK and ROK blocked hypoxic enhancement of CPAinduced CCE, suggesting interference with this facilitation (Figs. 2 and 3) . Thus MLCK and ROK antagonists appeared to block [Ca 2ϩ ] i responses to hypoxia by inhibiting hypoxic release of Ca 2ϩ from the SR and hypoxic facilitation of the transduction pathways leading to SOCC activation; however, if SR Ca 2ϩ stores acted upon by hypoxia differed from those acted upon by CPA, as suggested by some investigators (20, 24, 25, 62) , hypoxic facilitation of transduction pathways leading to SOCC activation would not necessarily be implicated by our results. More work is needed to clarify the mechanisms by which hypoxia activates CCE.
Hypoxia activated MLCK and ROK in PASMC and pulmonary arteries, leading to MLC phosphorylation and contraction that was inhibited by ML-9 or Y-27632 (33, 38, 68, 69, 83) . Inhibition of HPV in isolated lungs by Y-27632 has also been reported (16, 47) . Our results confirm these findings and, in addition, demonstrate inhibition of HPV in isolated lungs by ML-9, ML-7, and HA-1077 (Figs. 5 and 6 ). Although MLCK and ROK antagonists may have blocked HPV by inhibiting actin-myosin cross-bridge cycling and contraction, as commonly assumed, our results in PASMC (Fig. 1) suggest that they also may have acted by inhibiting Ca 2ϩ signaling. This deduction assumes that the behavior of our in vitro PASMC was similar to that of PASMC in vivo. In support of this assumption, acute hypoxia caused a rapid reversible increase in [Ca 2ϩ ] i in our PASMC (but not in similarly treated aortic smooth muscle cells), which was half-maximal at 39 mmHg PO 2 and inhibited by exposure to Ca 2ϩ -free medium or antagonists of voltage-and store-operated channels (66) . Although these response characteristics were shared by HPV in isolated rat lungs (77) , more direct evidence is needed to confirm that Ca 2ϩ signaling in our PASMC reflected that of in vivo cells.
Because HPV in isolated lungs and [Ca 2ϩ ] i responses to hypoxia in PASMC depended on Ca 2ϩ influx through SOCC and VOCC (42, 66, 77) , we determined the effects of MLCK and ROK antagonists on responses to activation of VOCC with high extracellular [K ϩ ]. In PASMC, ML-9 and ML-7 blocked (Fig. 7) , suggesting inhibition of Ca 2ϩ entry through VOCC. To test this possibility, we measured effects of ML-9 and nifedipine on the rate at which Mn 2ϩ quenched fura 2 fluorescence in PASMC perfused with Ca 2ϩ -free KRBS containing 60 mM KCl to activate VOCC and 50 M SKF-96365 to block entry through SOCC and nonspecific cation channels (65, 66) . Similar to nifedipine, ML-9 abolished the increased quenching caused by high [K ϩ ] (Fig. 8) , suggesting that ML-9 blocked Ca 2ϩ entry through VOCC. Thus the effects of ML-9 on the [Ca 2ϩ ] i response to hypoxia (Fig. 1 ) may have been due in part to inhibition of VOCC, which contributed to this response in rat distal PASMC (66) . In contrast, neither Y-27632 nor HA-1077 altered [Ca 2ϩ ] i responses to high extracellular [K ϩ ] (Fig. 7) . This result suggests that ROK was not activated in PASMC under normoxic conditions. Consistent with this possibility, neither Y-27632 nor HA-1077 altered CCE in PASMC during normoxia, whereas ML-9 caused inhibition (Fig. 2) . (18, 27, 32, 37, 59 ), but not all (22, 47, 63) , studies of airway and vascular tissue. These effects may have occurred because ROK had been activated by paracrine mediators released from depolarized neural, endothelial, or other cells present in isolated lungs, vessels, and airways, but not our PASMC preparation. Consistent with this possibility, we found that Y-27632 blocked responses to high [K ϩ ] in intact, but not endotheliumdenuded, rat distal pulmonary arteries (78) .
IC 50 values of MLCK and ROK antagonists vs. Ca 2ϩ signaling during hypoxia in PASMC (Fig. 1C) were slightly greater than IC 50 values vs. kinase activities of the purified enzymes measured in vitro (3, 12, 48, 55) and less than IC 50 values vs. HPV in isolated lungs (Fig. 6B) ; however, they were comparable to concentrations found by other laboratories to inhibit smooth muscle contraction or MLC phosphorylation induced by high extracellular [K ϩ ] or [Ca 2ϩ ] i in the case of ML-9 and ML-7 (23, 37, 48, 78, 80) or by G protein-linked receptor agonists or GTP␥S in the case of Y-27632 and HA-1077 (10, 18, 22, 26, 37, 40, 55, 59, 63, 78) . Since MLCK and ROK antagonists act by competing with ATP for its binding sites on the enzymes, these differences could be due to different concentrations of ATP and/or enzymes among preparations (3, 40, 48, 55) . Moreover, in isolated lungs and smooth muscle preparations, MLCK and ROK activity may have been increased by endogenous or exogenous agonists, thereby increasing antagonist concentrations required for inhibition (26, 47, 55, 70) , an effect that would not be present in purified enzyme preparations (3, 12, 48, 55) . For example, the presence of an endogenous agonist might explain why HPV was slightly, but significantly, increased by 30 M ML-9 or ML-7 during the fourth exposure of our isolated lungs to hypoxia (Fig. 6A) . Since MLCK antagonists blocked Ca 2ϩ influx and nitric oxide production in endothelial cells (74) , they may have decreased endothelium-dependent vasodilation, a known modulator of HPV (21) . An exogenous agonist might explain why IC 50 for Y-27632 vs. HPV was 31.2 M in our isolated lungs, which were exposed to ANG II and hypoxia, but only 0.06 M in the lungs studied by Robertson et al. (47) , which were exposed to hypoxia alone. Alternatively, this difference in IC 50 could be related to the phase of HPV, since phase 2 HPV in pulmonary arteries was more sensitive to Y-27632 than phase 1 (47) (Fig.  1) by blocking Ca 2ϩ release from the SR (Fig. 4) , Ca 2ϩ entry through SOCC (Figs. 2 and 3) , and Ca 2ϩ entry through VOCC (Figs. 7 and 8) . One possible explanation is that antagonistinduced decreases in [P-MLC] inhibited myosin motors and/or altered the cytoskeleton in a manner that prevented necessary maintenance or rearrangement of spatial relationships among the cellular components of the hypoxic response. For example, hypoxic activation of SR Ca 2ϩ release by cADP-ribose (13, 79) and/or short-lived reactive oxygen species released from mitochondria (75, 76) might require proximity of mitochondria to SR. SOCC activation might depend on translocation of channel proteins to the plasma membrane (5, 51) and/or assembly of channels and regulatory proteins into signaling scaffolds (4, 7, 8, 81) . Maintenance of VOCC activation might require local sequestration of inactivating Ca 2ϩ by mitochondria transported to the plasma membrane (6, 11, 15) or stimulation of integrin-linked transduction pathways by increased cytoskeletal tension (34) .
Such possibilities would be consistent with accumulating evidence that the cytoskeleton plays an important role in Ca 2ϩ signaling of smooth muscle contraction. In vascular and airway smooth muscle, antagonists of actin polymerization inhibited contractile responses (1, 9, 36) and currents through L-type VOCC (41) . Depletion of focal adhesion kinase, which binds to integrins that link the cytoskeleton to the extracellular matrix and phosphorylates several cytoskeletal proteins, inhibited agonist-induced increases in [Ca 2ϩ ] i , MLC phosphorylation, and contraction (60) . Anti-␣-integrin antibody or fibronectin, an extracellular matrix protein that binds to integrins, activated currents through L-type VOCC in vascular smooth muscle (82) . This effect was inhibited by antibodies against focal adhesion kinase and the cytoskeletal proteins vinculin and paxillin. In endothelial cells, inhibition of MLCK with ML-9 blocked CCE (43, 58, (72) (73) (74) . Extracted MLCK coprecipitated with actin and spectrin, a cytoskeletal protein that links to actin and plasmalemmal proteins (4, 8) . CCE was blocked by stabilizing or depolymerizing the actin cytoskeleton (43), preventing interaction of spectrin with protein 4.1, which tethers spectrin to the plasma membrane and regulates spectrin-actin cross-linking (81), or blocking binding of protein 4.1 to TRPC4 protein, which is thought to be a component of SOCC (7) . Thus it seems possible that myosin motors or cytoskeletal effects of actin-myosin interaction could be essential components of Ca 2ϩ signaling in PASMC during hypoxia. Whether this is true and whether antagonists of MLCK and ROK inhibited hypoxic Ca 2ϩ signaling by interfering with these components remain to be determined.
In summary, our results indicate that the MLCK antagonists ML-9 and ML-7 and the ROK antagonists Y-27632 and HA-1077 blocked HPV in isolated lungs and increases in [Ca 2ϩ ] i induced by hypoxia in distal PASMC. The latter effect appeared to be due to inhibition of Ca 2ϩ release from the SR, Ca 2ϩ entry through SOCC, and Ca 2ϩ entry through VOCC. If the behavior of our PASMC resembled that of PASMC in vivo, these results suggest that MLCK and ROK antagonists blocked HPV by inhibiting Ca 2ϩ signaling, as well as the actin-myosin interaction.
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